Karyopharm Therapeutics Inc
Follow $KPTI
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $KPTI by emailVeridion Score
BETALOW CONF · 6 of 6 factors measuredsnapshot unavailable for KPTI. Cause unavailable.
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is KPTI moving today?
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
KPTI overview
Related filings and maps
Congress activity in KPTI
No receipt-qualified Congressional disclosure is present for KPTI in the cached public ledger.
KPTI contract awards, year to date.
Public federal awards linked to this ticker.
KPTI lobbying filings, year to date.
Registered lobbying filings matched to Karyopharm Therapeutics Inc.
SIDLEY AUSTIN LLP